SCHEMBL6038807

SCHEMBL6038807

O=S(=O)(Nc1nccnc1OCCc1cccs1)c1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
ALDH1A1 P00352 5/20 0.43
ALOX12 P18054 2/20 0.43
POLB P06746 2/20 0.43
RECQL P46063 1/20 0.43
ESR2 Q92731 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
F2 P00734 1/20 0.42
CCR2 P41597 2/20 0.41
EDNRB P24530 1/20 0.39
EDNRA P25101 1/20 0.39
GAA P10253 1/20 0.39
KDM4E B2RXH2 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038483 0.90 MEN1 (0.46) KMT2AMEN1ALDH1A1POLBRECQL
SCHEMBL6038759 0.90 KMT2A (0.44) KMT2AMEN1ALDH1A1POLBRECQL
SCHEMBL6038492 0.90 EDNRB (0.47) KMT2AMEN1ALDH1A1POLBRECQL
SCHEMBL6038820 0.88 KMT2A (0.45) KMT2AMEN1ALDH1A1POLBRECQL
SCHEMBL6039027 0.87 MEN1 (0.44) KMT2AMEN1ALDH1A1POLBRECQL
SCHEMBL6038427 0.87 MEN1 (0.46) KMT2AMEN1ALDH1A1POLBRECQL
SCHEMBL6038900 0.82 KMT2A (0.53) KMT2AMEN1ALDH1A1ALOX12POLB
SCHEMBL6039220 0.80 MEN1 (0.53) KMT2AMEN1ALDH1A1ALOX12F2
SCHEMBL6039264 0.76 KDM4E (0.62) KMT2AMEN1ALDH1A1POLBHSD17B10
SCHEMBL6038333 0.75 MEN1 (0.59) KMT2AMEN1ALDH1A1POLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KMT2A 4190/4885MEN1 2431/4885ALDH1A1 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.